Clinical trials: Interstitial Lung Disease With Systemic Sclerosis
Pirfenidone, Connective Tissue Diseases
Immunosuppressant Combined With Pirfenidone in CTD-ILD
A prospective cohort study was used to observe the efficacy and safety of different immunosuppressive agents with/wo pirfenidone on CTD-ILD patients in Qilu Hospital of Shandong University for 36 months.The main research…
- Conditions
- Pirfenidone, Connective Tissue Diseases, Interstitial Lung Disease
- Trial name
- NCT04928586
- Testing
- Pirfenidone, DMARDs
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qilu Hospital of Shandong University
Scleroderma, Systemic, Fibrosis; Skin
Western Sweden Systemic Sclerosis Project
The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment…
- Conditions
- Scleroderma, Systemic, Fibrosis; Skin, Fibrosis Lung, Interstitial Lung Disease Due to Systemic Disease
- Trial name
- WESST (NCT07345052)
- Testing
- No Intervention: Observational Cohort
- Where
- Sweden
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
Connective Tissue Diseases, Interstitial Lung Disease
Connective Tissue Diseases and Lung Manifestations
Despite a number of prospective studies already initiated in the past years, the current epidemiology and course of interstitial lung disease (ILD) and pulmonary hypertension (PH) in patients with connective tissue disease (CTD)…
- Conditions
- Connective Tissue Diseases, Interstitial Lung Disease, Systemic Sclerosis
- Trial name
- Colipris (NCT04095351)
- Testing
- Pulmonary function test, Imaging, Blood sampling
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Medical University Innsbruck
Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment
Progressive SSc is an entity with limited therapeutic alternatives and a survival rate of less than 45% within the first 3 to 5 years.
- Conditions
- Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis
- Trial name
- NCT07542067
- Testing
- Mesenchymal Stem Cells from Wharton´s jelly
- Where
- Colombia
- Volunteers
- 1 people
- Sponsor
- Fundación Neumologica Colombiana
Interstitial Lung Disease, Pulmonary Hypertension
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis
This study aims to evaluate a noninvasive magnetic resonance imaging technique using hyperpolarized xenon gas to measure lung function in adults with interstitial lung disease, pulmonary hypertension, and systemic sclerosis.
- Conditions
- Interstitial Lung Disease, Pulmonary Hypertension, Systemic Sclerosis
- Trial name
- NCT07821398
- Testing
- Hyperpolarized 129 Xenon Gas
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Interstitial Lung Disease
Patient-Reported Outcome Study of Project ECHO for ILD
The study will assess whether patients of providers participating in Project ECHO for ILD experience reduced stress, including financial stress, based on their ability to receive timely and local care and services, The study will…
- Trial name
- NCT05450276
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Interstitial Lung Disease With Systemic Sclerosis
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at…
- Trial name
- EVER-ILD 3 (NCT06549231)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 102 people
- Sponsor
- University Hospital, Tours
Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement
Progressive SSc is an entity with limited therapeutic alternatives and with asurvival rate of less than 45% in the first 3 to 5 years.
- Conditions
- Systemic Sclerosis Pulmonary, Pulmonary Hypertension, Pulmonary Fibrosis
- Trial name
- NCT04432545
- Testing
- Mesenchymal Stem Cells from Wharton ́s jellyintravenous infusion of Mesenchymal Stem Cells from Wharton ́s jelly
- Where
- Colombia
- Sponsor
- Universidad de la Sabana
Scleroderma, Systemic, Lung Diseases, Interstitial
Functional Exercise Tests in Patients With Systemic Sclerosis
The aim of the study is to examine the validity of peripheral oxygen saturation measurement during the 6-minute walk test in patients with Systemic Sclerosis (SSc) and to examine the utility of two other functional tests as…
- Conditions
- Scleroderma, Systemic, Lung Diseases, Interstitial, Pulmonary Arterial Hypertension, Acroosteolysis
- Trial name
- NCT04650659
- Testing
- 6-minute walk test part one, 6-minute walk test part two, 1-minute sit-to-stand test
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- University of Aarhus
Systemic Sclerosis
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
The main purpose of the study is to investigate the efficacy on cutaneous thickness and the safety of Nemolizumab in adult patients with systemic sclerosis after a 52-week treatment period and to select the optimal dose for this…
- Trial name
- NCT07047690
- Testing
- Nemolizumab
- Where
- 3 sites in United States, Switzerland
- Volunteers
- 162 people
- Sponsor
- Galderma R&D
Systemic Sclerosis With and Without Interstitial Lung Disease
A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)
The purpose of the MK-2225-002 (A1334-02) study is to evaluate the safety and tolerability of MK-2225 (ACE-1334) plus standard of care (SOC) in participants with Systemic Sclerosis (SSc) following multiple doses.
- Trial name
- NCT04948554
- Testing
- MK-2225
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 5 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Scleroderma, Systemic, Sclerosis, Systemic
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
The primary objective of this study is to evaluate the safety, tolerability, and efficacy of pomalidomide in the treatment of patients with systemic sclerosis with interstitial lung disease.
- Conditions
- Scleroderma, Systemic, Sclerosis, Systemic, Systemic Scleroderma, Systemic Sclerosis
- Trial name
- NCT01559129
- Testing
- Pomalidomide (CC-4047)
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 23 people
- Sponsor
- Celgene
Systemic Lupus Erythematosus, Lupus Nephritis
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- BAH242 (NCT06350110)
- Testing
- CD19- BCMA CAR-T cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Essen Biotech
Interstitial Lung Disease Due to Systemic Disease
Registry of Autoimmune Interstitial Lung Disease
Interstitial lung diseases (ILD) constitute a group of entities characterized by inflammation and/or fibrosis of the lung parenchyma.
- Trial name
- EPIMAR (NCT05365009)
- Testing
- Multidisciplinary aproach
- Where
- Argentina
- Volunteers
- 1,000 people
- Sponsor
- EPIMAR registry
Lung Diseases, Pulmonary Fibrosis
Scleroderma Lung Disease
To evaluate the efficacy and safety of cyclophosphamide versus placebo for the prevention and progression of symptomatic pulmonary disease in patients with systemic sclerosis.
- Conditions
- Lung Diseases, Pulmonary Fibrosis, Systemic Scleroderma, Scleroderma, Systemic
- Trial name
- SLS (NCT00004563)
- Testing
- Cyclophosphamide
- Volunteers
- 158 people
- Sponsor
- The University of Texas Health Science Center, Houston
Systemic Sclerosis With Lung Involvement, Systemic Sclerosis
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement.
- Conditions
- Systemic Sclerosis With Lung Involvement, Systemic Sclerosis, Interstitial Lung Disease
- Trial name
- SSc-mILD (NCT05785065)
- Testing
- Mycophenolate Mofetil
- Where
- 3 sites in Canada
- Volunteers
- 35 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
- Trial name
- ATHENA-SSc-ILD (NCT05270668)
- Testing
- Tulisokibart, Companion diagnostic ( CDx)
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 154 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Systemic Sclerosis, Interstitial Lung Disease
Interstitial Lung Disease Trajectories in Patients With Systemic Sclerosis
Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. In patients with systemic sclerosis, interstitial lung disease (ILD) concerns almost 50 % of patients and…
- Trial name
- SCLEROPIDEVOL (NCT05345795)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Central Hospital, Nancy, France
Scleroderma, Systemic, Skin Sclerosis
A Study of the Efficacy and Safety of Rituximab in Participants With Systemic Sclerosis
This study evaluates the efficacy and safety of rituximab compared with placebo in SSc patients. This study consists of a 24-week, double-blind, placebo-controlled period followed by a 24-week active drug treatment period.
- Conditions
- Scleroderma, Systemic, Skin Sclerosis, Lung Fibrosis, Autoimmune Diseases
- Trial name
- DesiReS (NCT04274257)
- Testing
- Double-Blind Rituximab
- Where
- 4 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Tokyo University
Connective Tissue Diseases
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim to assess the efficacy and safety of belimumab on reducing the…
- Trial name
- NCT06716606
- Testing
- Belimumab
- Where
- 41 sites in United States, Argentina and 9 more
- Volunteers
- 514 people
- Sponsor
- GlaxoSmithKline